about
Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitorStructure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrasesComprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady state.Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance.NMR and pattern recognition studies on liver extracts and intact livers from rats treated with alpha-naphthylisothiocyanate.In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set.The role of metabonomics at the interface between drug metabolism and safety assessment.Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.Use of the Øie-Tozer model in understanding mechanisms and determinants of drug distribution.Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions.Metabonomic deconvolution of embedded toxicity: application to thioacetamide hepato- and nephrotoxicity.In silico prediction of total human plasma clearance.Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding.In silico human and rat Vss quantitative structure-activity relationship models.Integrated metabonomic analysis of bromobenzene-induced hepatotoxicity: novel induction of 5-oxoprolinosisHigh-resolution magic angle spinning (1)H NMR spectroscopy of intact liver and kidney: optimization of sample preparation procedures and biochemical stability of tissue during spectral acquisitionEditorial [Hot topic: Drug Design from the ADME/PK Perspective: Does Chemical Intuition Suffice in Multifaceted Drug Discovery? (Guest Editors: Franco Lombardo & Nigel J. Waters)]
P50
Q27685195-A7EAEB9B-E6B0-4711-96EC-B4EEE08FFBBCQ27685270-0FE2E5B2-7A7F-419E-B5CA-21B3567D188CQ30593572-1B866A8A-1BA2-46D1-91BF-AC62E45F2C0AQ30593578-4EB11803-229D-4B3D-8CA0-1C05B89174A7Q30702501-3019F242-D434-4768-8721-65626A0A292EQ33482357-9E7C82E2-ED10-46AD-89F9-D8F426757D13Q37802899-061BD109-7F88-40F6-A6FC-E8C580728C0DQ39591482-427D6DE3-F791-40CE-8FFB-1CC1F8AAFEC3Q39884969-02C78F17-EE56-42D1-8820-99663C2BDE63Q40100581-F286BA70-7C06-4B0A-A056-E02CA3434E8AQ40111742-967B6A0E-0624-445F-9EDE-6F0B3AD4B065Q46439569-BB625F3B-44DE-4B01-B6E8-0661D2D50C43Q47598699-D3216DD7-EFB5-42ED-BC54-C0C7AFA9B94CQ47888465-BAD7ED08-B16C-4B16-BC75-318A2DD52BE8Q51945806-AD472E05-0BD8-49FD-B7AF-4F290224C6A1Q57099717-35AA5A11-D048-42D2-88E8-FDA4B00B67C1Q57102191-4B078512-1C45-4570-86AE-5FAB7D288C05Q57815260-9C006A21-7575-46B8-9A15-923327731583
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nigel J Waters
@nl
Nigel J Waters
@sl
Nigel J. Waters
@en
Nigel J. Waters
@es
type
label
Nigel J Waters
@nl
Nigel J Waters
@sl
Nigel J. Waters
@en
Nigel J. Waters
@es
prefLabel
Nigel J Waters
@nl
Nigel J Waters
@sl
Nigel J. Waters
@en
Nigel J. Waters
@es
P106
P1153
7102435796
P21
P31
P496
0000-0002-5063-295X